Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,848 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70 - NCT06273800Recruiting
Chemo timing and the menstrual cycle in breast cancer
This study tests whether the timing of chemotherapy during your menstrual cycle affects how well it works in triple-negative breast cancer. Women with regular periods who are about to start chemo before surgery may be eligible.
Amsterdam, North HollandAges 18–59 - NCT06263153RecruitingPhase 2
Futibatinib and durvalumab before bladder cancer surgery
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT05322460Recruiting
Online support program for long-term breast cancer survivors
This study tests a web-based program to support women who have finished breast cancer treatment and have no signs of active disease. It may help improve how you cope, stay informed, and manage life after treatment.
PamplonaAges 18–99 - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Birmingham, AlabamaAges 1–18 - NCT06200155RecruitingPhase 2
Psilocybin therapy for advanced cancer patients with anxiety or depression
This trial tests whether a drug called psilocybin, given with therapy, can help people with advanced cancer who are feeling anxious or depressed. You must have a stable cancer and be willing to travel to Houston for treatment.
Houston, TexasAges 25 years+ - NCT06160323Recruiting
Pain block for inoperable pancreatic cancer
This trial tests whether an early nerve block during endoscopy can better control pain from pancreatic cancer compared to waiting and using standard treatments.
Hong Kong, Hong KongAges 18 years+ - NCT06150417RecruitingPhase 2
Study of extra radiation for prostate cancer spread to few spots
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
New York, New YorkAges 18 years+ - NCT06150898RecruitingPhase 2
Ketorolac and pregabalin for estrogen receptor positive breast cancer before surgery
This trial tests whether two medications, ketorolac (a pain reliever) and pregabalin (a nerve pain drug), can help treat estrogen receptor (ER) positive breast cancer when taken before surgery. It may offer better pain control and possibly improve cancer outcomes.
Brussels, Brussels CapitalAges 18–70 - NCT06123338RecruitingPhase 2
Pembrolizumab plus chemo and trastuzumab for HER2+ stomach cancer
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Boston, MassachusettsAges 18 years+ - NCT06085729RecruitingPhase 1/Phase 2
Study of ADI-PEG20 with chemo for aggressive prostate cancer
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT06023576RecruitingPhase 2
Blood pressure control during breast cancer chemo
This study tests whether careful blood pressure management can help protect the heart during certain types of chemotherapy (anthracyclines) for breast cancer. Participants will use a smart blood pressure device and may also do an exercise test.
Basking Ridge, New JerseyAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05946577Recruiting
Links tinnitus and hearing changes after head and neck cancer treatment
This study looks at how tinnitus (ringing in the ears) and hearing problems may develop after radiotherapy alone or with certain chemotherapy for high-risk head and neck cancer. The goal is to better understand who is more likely to experience these side effects.
ParisAges 18 years+ - NCT05916196RecruitingPhase 2
FES PET/CT scan for uterine cancer spread
This Phase 2 study tests how well a special PET/CT scan (called FES PET/CT) can find uterine cancer and its spread. It may help doctors see where cancer is active, which can guide future treatment decisions.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05887609RecruitingPhase 2
Maintenance treatment for FRalpha-positive ovarian or endometrial cancer
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
Irvine, CaliforniaAges 18–100 - NCT05873192RecruitingPhase 2
Talazoparib plus enzalutamide before prostate surgery
This trial studies whether taking talazoparib and enzalutamide before surgery can shrink or control prostate cancer. If treatment works, it may make the cancer easier to remove with a radical prostatectomy.
Houston, TexasAges 18 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05819892RecruitingPhase 1
Dostarlimab with chemo and radiation for advanced womb cancer
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Houston, TexasAges 18 years+ - NCT05796375RecruitingPhase 2
Urine testing instead of repeat bladder scope checks
This Phase 2 study tests whether urine tests can help monitor “non-muscle-invasive” bladder cancer without doing as many invasive bladder scopes (cystoscopies). If you qualify, you may be able to replace some scope visits with urine sample testing while still keeping close watch for cancer coming back.
West Haven, ConnecticutAges 18 years+ - NCT05792150Recruiting
Registry for young women with certain early breast cancer treatments
This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.
Baden-Baden, Baden-WurttembergAges 18–60 - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05716893RecruitingPhase 2
Aerobic exercise program for people getting breast cancer treatment
This Phase 2 study tests whether a supervised aerobic (cardio) training program can improve health and exercise capacity for people receiving treatment for primary breast cancer. You may join if you currently do very little moderate-to-vigorous exercise and can safely complete a special treadmill test that measures breathing and heart response.
Basking Ridge, New JerseyAges 18 years+ - NCT05704829RecruitingPhase 2
Trastuzumab-deruxtecan before surgery for HER2-positive early breast cancer
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
Baden-Baden, Baden-WurttembergAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,848 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.